IMGN News and Press, ImmunoGen Inc. From 05/01/20

ImmunoGen (NASDAQ: IMGN ): Q1 GAAP EPS of -$0.17 misses by $0.02 . More news on: ImmunoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Pivotal SORAYA Trial Initiated for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer Data from FORWARD II Avastin ® Expansion Cohort in Platinum-Agnostic Ovarian Cancer Selected for Oral Presentation at ASCO Pre-Clinical Data on Next Generation Anti-FRα A...

If you’re searching for the top penny stocks right now, it may be as simple as reading some broader market headlines. While most of these cheap stocks tend to march to the sound of their own drum, in some cases certain sectors will see a strong trend. Right now, thanks to COVID 19, n...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 1, 2020 to discuss its first quarter operating results. Management wil...

Gainers: IFRX   +40.1% .   CERS   +9.9% . NVAX   +8.3% . TWOU   +4.7% . More news on: InflaRx N.V., Cerus Corporation, Novavax, Inc., Stocks on the move, , Read more ...

Bull markets are born on pessimism, grown on skepticism, mature on optimism and die on euphoria. - Sir John Templeton One of the best times for you to invest in a stock is when it tumbled far below its true worth. This usually occurs during a downturn like this Corona bear market. Howeve...

Today we will see why ImmunoGen ( IMGN ) can be an attractive pick in 2020. Company overview ImmunoGen is a clinical-stage biopharmaceutical company focused on the development of next-generation ADCs (antibody-drug conjugates) to target multiple cancer indications. The company’s l...

Shares of ImmunoGen (NASDAQ: IMGN) were sinking 11.1% lower as of 11:03 a.m. EST on Tuesday. The decline appears to be the result of profit-taking following the biotech's blowout fourth-quarter results announced on Friday. ImmunoGen handily beat Wall Street's top- and bottom-line estimates...

Shares of biotech ImmunoGen (NASDAQ: IMGN) soared by 27% after the company  beat financial expectations  for its fiscal first quarter and reassured investors about the prospects for its lead drug candidate as a treatment for ovarian cancer. Its revenues, which currently come from l...

ImmunoGen (NASDAQ: IMGN)  floundered throughout much of 2019, with the stock down more than 50% year to date by October. But some encouraging news from a late-stage clinical study evaluating mirvetuximab soravtansine renewed investors' enthusiasm soon afterward. ImmunoGen sto...